Chunghwa Chemical Synthesis & Biotech Co Ltd (CCSB, 中化合成生技) yesterday said that it is ready to produce remdesivir, an experimental antiviral drug being studied as a treatment for COVID-19, if the government determines that it is safe and effective against the novel coronavirus that causes the disease.
The company earlier this week completed the synthesis of 4.73g of remdesivir with a purity of 99.72 percent.
“We spent about two weeks replicating the drug. The synthesis part was not time-consuming, but we spent some time waiting for ingredients from abroad,” CCSB spokesman Eason Wang (王冠傑) told the Taipei Times by telephone.
The company purchased the processed ingredients from overseas, as it lacks low-temperature equipment to proceed with synthesis, he said.
“As some chemical reactions have to take place at a very low temperature — about minus-78°C — when combining the compounds to make remdesivir, a special device is necessary,” Wang said, adding that the firm is considering buying such equipment to enable full production.
CCSB, a manufacturer of active pharmaceutical ingredients, was the latest local institution or company to succeed in replicating the experimental drug after Academia Sinica and Formosa Laboratories Inc (台耀化學).
Remdesivir, developed by US-based Gilead Sciences Inc, has shown promising results in fighting the novel coronavirus in an early analysis of overseas studies, Wang said.
Taiwan is also conducting clinical trials to test the drug’s efficacy, he said.
As no definitive conclusion on whether remdesivir is an effective treatment for COVID-19 has been made and Gilead has a patent for the drug, CCSB does not plan to mass-produce it, unless the government makes it compulsory for local companies to produce such drugs, Wang said.
With a stable supply of ingredients from overseas, CCSB could manufacture 30kg of remdesivir within 12 weeks, which should be enough to treat 30,000 patients, who would each need about 1.1g, he said.
“As the spread of COVID-19 seems to have abated in Taiwan,” with the Central Epidemic Command Center yesterday reporting zero new cases for the third time this week, “we do not expect high demand for the drug domestically,” Wang said.
However, local regulators might consider allowing companies to produce the drug to help other nations deal with escalating outbreaks of the disease, as the government earlier this month donated masks to affected countries, he said.
TAKING STOCK: A Taiwanese cookware firm in Vietnam urged customers to assess inventory or place orders early so shipments can reach the US while tariffs are paused Taiwanese businesses in Vietnam are exploring alternatives after the White House imposed a 46 percent import duty on Vietnamese goods, following US President Donald Trump’s announcement of “reciprocal” tariffs on the US’ trading partners. Lo Shih-liang (羅世良), chairman of Brico Industry Co (裕茂工業), a Taiwanese company that manufactures cast iron cookware and stove components in Vietnam, said that more than 40 percent of his business was tied to the US market, describing the constant US policy shifts as an emotional roller coaster. “I work during the day and stay up all night watching the news. I’ve been following US news until 3am
Six years ago, LVMH’s billionaire CEO Bernard Arnault and US President Donald Trump cut the blue ribbon on a factory in rural Texas that would make designer handbags for Louis Vuitton, one of the world’s best-known luxury brands. However, since the high-profile opening, the factory has faced a host of problems limiting production, 11 former Louis Vuitton employees said. The site has consistently ranked among the worst-performing for Louis Vuitton globally, “significantly” underperforming other facilities, said three former Louis Vuitton workers and a senior industry source, who cited internal rankings shared with staff. The plant’s problems — which have not
TARIFF CONCERNS: The chipmaker cited global uncertainty from US tariffs and a weakening economic outlook, but said its Singapore expansion remains on track Vanguard International Semiconductor Corp (世界先進), a foundry service provider specializing in producing power management and display driver chips, yesterday withdrew its full-year revenue projection of moderate growth for this year, as escalating US tariff tensions raised uncertainty and concern about a potential economic recession. The Hsinchu-based chipmaker in February said revenues this year would grow mildly from last year based on improving supply chain inventory levels and market demand. At the time, it also anticipated gradual quarter revenue growth. However, the US’ sweeping tariff policy has upended the industry’s supply chains and weakened economic prospects for the world economy, it said. “Now
COLLABORATION: Given Taiwan’s key position in global supply chains, the US firm is discussing strategies with local partners and clients to deal with global uncertainties Advanced Micro Devices Inc (AMD) yesterday said it is meeting with local ecosystem partners, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), to discuss strategies, including long-term manufacturing, to navigate uncertainties such as US tariffs, as Taiwan occupies an important position in global supply chains. AMD chief executive officer Lisa Su (蘇姿丰) told reporters that Taiwan is an important part of the chip designer’s ecosystem and she is discussing with partners and customers in Taiwan to forge strong collaborations on different areas during this critical period. AMD has just become the first artificial-intelligence (AI) server chip customer of TSMC to utilize its advanced
RSS